844
E. Goffin et al. / European Journal of Medicinal Chemistry 54 (2012) 834e844
[3] F. Lefranc, N. Sadeghi, I. Camby, T. Metens, O. Dewitte, R. Kiss, Present and
[25] F. Branle, F. Lefranc, I. Camby, J. Jeuken, A. Geurts-Moespot, S. Sprenger,
F. Sweep, R. Kiss, I. Salmon, Evaluation of the efficiency of chemotherapy in
in vivo orthotopic models of human glioma cells with and without 1p19q
deletions and in C6 rat orthotopic allografts serving for the evaluation of
surgery combined with chemotherapy, Cancer 95 (2002) 641e655.
[26] B. Sivasankaran, M. Degen, A. Ghaffari, M.E. Hegi, M.F. Hamou, M.C.S. Ionescu,
C. Zweifel, M. Tolnay, M. Wasner, S. Mergenthaler, A.R. Miserez, R. Kiss,
M.M. Lino, A. Merlo, R. Chiquet-Ehrismann, J.L. Boulay, Tenascin-C is a novel
RBPJk-induced target gene for notch signaling in gliomas, Cancer Res. 69
(2009) 458e465.
[27] N. Belot, R. Pochet, C.W. Heizmann, R. Kiss, C. Decaestecker, Extracellular
S100A4 stimulates the migration rate of astrocytic tumor cells by modifying
the organization of their actin cytoskeleton, Biochim. Biophys. Acta 1600
(2002) 74e83.
[28] M. Le Mercier, S. Fortin, V. Mathieu, I. Roland, S. Spiegl-Kreinecker, B. Haibe-
Kains, G. Bontempi, C. Decaestecker, W. Berger, F. Lefranc, R. Kiss, Galectin-1
proangiogenic and promigratory effects in the Hs683 oligodendroglioma
model are partly mediated through the control of BEX2 expression, Neoplasia
11 (2009) 485e496.
potential future issues in glioblastoma treatment, Expert Rev. Anticancer Ther.
6 (2006) 719e732.
[4] F. Lefranc, V. Facchini, R. Kiss, Pro-autophagic drugs: a novel means to combat
apoptosis-resistant cancers, with
a special emphasis on glioblastomas,
Oncologist 12 (2007) 1395e1403.
[5] R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J.B. Taphoorn, R.C. Janzer,
S.K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A.A. Brandes, J. Gijtenbeek,
C. Marosi, C.J. Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T. Gorlia,
M. Weller, D. Lacombe, J.G. Cairncross, R.O. Mirimanoff, Effects of radiotherapy
with concomitant and adjuvant temozolomide versus radiotherapy alone on
survival in glioblastoma in a randomised phase III study: 5-year analysis of the
EORTC-NCIC trial, Lancet Oncol. 10 (2009) 459e466.
[6] T. Kanzawa, I.M. Germano, T. Komata, H. Ito, Y. Kondo, S. Kondo, Role of
autophagy in temozolomide-induced cytotoxicity for malignant glioma cells,
Cell Death Differ. 11 (2004) 448e457.
[7] W.P. Roos, L.F. Batista, S.C. Naumann, W. Wick, M. Weller, C.F. Menck, B. Kaina,
Apoptosis in malignant glioma cells triggered by the temozolomide-induced
DNA lesion O6-methylguanine, Oncogene 26 (2007) 186e197.
[8] V. Mathieu, N. De Neve, M. Le Mercier, J. Dewelle, J.F. Gaussin, M. Dehoux,
R. Kiss, F. Lefranc, Combining bevacizumab with temozolomide increases the
anti-tumor efficacy of temozolomide in human glioblastoma orthotopic
xenograft model, Neoplasia 10 (2008) 1383e1392.
[9] H. Sontheimer, Malignant gliomas: perverting glutamate and ion homeostasis
for selective advantage, Trends Neurosci. 26 (2003) 543e549.
[10] H. Sontheimer, Ion channels and amino acid transporters support the growth
and invasion of primary brain tumors, Mol. Neurobiol. 29 (2004) 61e71.
[11] H. Sontheimer, An unexpected role for ion channels in brain tumor metastasis,
Exp. Biol. Med. (Maywood) 233 (2008) 779e791.
[29] L. Ingrassia, F. Lefranc, J. Dewelle, L. Pottier, V. Mathieu, S. Spiegl-Kreinecker,
S. Sauvage, M. El Yazidi, M. Dehoux, W. Berger, E. Van Quaquebeke, R. Kiss,
Structure-activity-relationship analysis of novel derivatives of narciclasine (an
amaryllidaceae isocarbostyril alkaloid) as potential anti-cancer agents, J. Med.
Chem. 52 (2009) 1100e1114.
[30] C. Decaestecker, O. Debeir, P. Van Ham, R. Kiss, Can anti-migratory drugs be
screened in vitro? A review of 2D and 3D assays for the quantitative analysis
of cell migration (review), Med. Res. Rev. 27 (2007) 149e176.
[31] C.D. Hurd, S. Hayao, Chromanones, thiochromanones, and 2,3-dihydro-4(1H)-
quinolones, J. Am. Chem. Soc. 76 (1954) 5065e5069.
[12] F. Lefranc, R. Kiss, The sodium pump alpha-1 subunit as a potential target to
combat apoptosis-resistant glioblastomas, Neoplasia 10 (2008) 198e206.
[13] F. Lefranc, T. Mijatovic, Y. Kondo, S. Sauvage, I. Roland, D. Krstic, V. Vasic,
P. Gailly, S. Kondo, G. Blanco, R. Kiss, Targeting the alpha-1 subunit of the
sodium pump (the Naþ/Kþ-ATPase) to combat glioblastoma cells, Neurosur-
gery 62 (2008) 211e222.
[14] V.A. Cuddapah, H. Sontheimer, Ion channels and the control of cancer cell
migration, Am. J. Physiol. Cell Physiol. 301 (2011) C541e549.
[15] S. Sebille, P. de Tullio, B. Becker, M.-H. Antoine, S. Boverie, B. Pirotte, P. Lebrun,
4,6-Disubstituted 2,2-dimethylchromans structurally related to the KATP
channel opener cromakalim: design, synthesis, and effect on insulin release
and vascular tone, J. Med. Chem. 48 (2005) 614e621.
[32] G. Canalini, I. Degani, R. Fochi, G. Spunta, Heteroaromatic cations. X. Hydro-
lysis of some chromylium perchlorate derivatives, Ann. Chim. 57 (1967)
1045e1072.
[33] G. Charest, L. Sanche, D. Fortin, D. Mathieu, B. Paquette, Glioblastoma treat-
ment: bypassing the toxicity of platinum compounds by using liposomal
formulation and increasing treatment efficiency with concomitant radio-
therapy, Int. J. Radiat. Oncol. Biol. Biophys. in press.
[34] M. Varasi, F. Thaler, A. Abate, C. Bigogno, R. Boggio, G. Carenzi, T. Cataudella,
R. Dal Zuffo, M.C. Fulco, M.G. Rozio, A. Mai, G. Dondio, S. Minucci, C. Mercurio,
Discovery, synthesis, and pharmacological evaluation of spiropiperidine
hydroxamic acid based derivatives as structurally novel histone deacetylase
(HDAC) inhibitors, J. Med. Chem. 54 (2011) 3051e3064.
[16] S. Sebille, D. Gall, P. de Tullio, X. Florence, P. Lebrun, B. Pirotte, Design,
synthesis and pharmacological evaluation of R/S-3,4-dihydro-2,2-dimethyl-6-
halo-4-(phenylaminocarbonylamino)-2H-1-benzopyrans: towards tissue-
selective pancreatic B-cells KATP channel openers structurally related to
(ꢂ)-cromakalim, J. Med. Chem. 49 (2006) 4690e4697.
[35] R.G. Schmidt, E.K. Bayburt, S.P. Latshaw, J.R. Koenig, J.F. Daanen,
H.A. McDonald, B.R. Bianchi, C. Zhong, S. Joshi, P. Honore, K.C. Marsh, C.H. Lee,
C.R. Faltynek, A. Gomtsyan, Chroman and tetrahydroquinoline ureas as potent
TRPV1 antagonists, Bioorg. Med. Chem. Lett. 21 (2011) 1338e1341.
[36] R. Reilly, H. McDonald, P. Puttfarcken, S. Joshi, L. Lewis, M. Pai, P. Franklin, J.
Segreti, T. Neelands, P. Han, J. Chen, P. Mantyh, J. Ghilardi, T. Turner, E. Voight,
J. Daanen, R. Schmidt, A. Gomtsyan, M. Kort, C. Faltynek, P. Kym P, Novel
TRPV1 receptor antagonists that partially block acid activation: in vitro
pharmacology predicts effects on core body temperature and in vivo efficacy,
J. Pharmacol. Exp. Ther. in press.
[17] S. Sebille, P. de Tullio, X. Florence, B. Becker, M.-H. Antoine, C. Michaux,
J. Wouters, B. Pirotte, P. Lebrun, New R/S-3,4-Dihydro-2,2-dimethyl-6-halo-4-
(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to
(ꢂ)-cromakalim as tissue-selective pancreatic beta-cell KATP channel openers,
Bioorg. Med. Chem. 16 (2008) 5704e5719.
[18] X. Florence, S. Sebille, P. de Tullio, P. Lebrun, B. Pirotte, New R/S-3,4-dihydro-
2,2-dimethyl-2H-1-benzopyrans as KATP channel openers: modulation of the
4-position, Bioorg. Med. Chem. 17 (2009) 7723e7731.
[19] P. de Tullio, S. Boverie, B. Becker, M.-H. Antoine, Q.A. Nguyen, P. Francotte,
S. Counerotte, S. Sebille, B. Pirotte, P. Lebrun, 3-Alkylamino-4H-1,2,4-
benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers:
effect of 6,7-disubstitution on potency and tissue selectivity, J. Med. Chem. 48
(2005) 4990e5000.
[20] P. de Tullio, B. Becker, S. Boverie, M. Dabrowski, P. Wahl, F. Somers, S. Sebille,
R. Ouedraogo, J.B. Hansen, P. Lebrun, B. Pirotte, Toward tissue-selective
pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-
4H-1,2,4-benzothiadiazine 1,1-dioxides, J. Med. Chem. 46 (2003) 3342e3353.
[21] H. Hibino, A. Inanobe, K. Furutani, S. Murakami, I. Findlay, Y. Kurachi, Inwardly
rectifying potassium channels: their structure, function, and physiological
roles, Physiol. Rev. 90 (2010) 291e366.
[22] M.L. Olsen, H. Sontheimer, Mislocalization of Kir channels in malignant glia,
Glia 46 (2004) 63e73.
[23] G. Tan, S.Q. Sun, D.L. Yuan, Expression of Kir 4.1 in human astrocytic tumors:
correlation with pathologic grade, Biochem. Biophys. Res. Commun. 367
(2008) 743e747.
[24] L.M. Simar, K.T. Kahle, V. Gerzanich, Molecular mechanisms of microvascular
failure in central nervous system injury e synergistic roles of NKCC1 and
SUR1/TRPM4, J. Neurosurg. 113 (2010) 622e629.
[37] K.M. Mahar Doan, J.E. Humphreys, L.O. Webster, S.A. Wring, L.J. Shampine,
C.J. Serabit-Singh, K.K. Adkinson, J.W. Polli, Passive permeability and P-
glycoprotein-mediated efflux differentiate central nervous system (CNS) and
non-CNS marketed drugs, J. Pharmacol. Exp. Ther. 303 (2002) 1029e1037.
[38] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and
computational approaches to estimate solubility and permeability in drug
discovery and development settings, Adv. Drug Deliv. Rev. 23 (1997) 3e25.
[39] H. Pajouhesh, G.R. Lenz, Medicinal chemical properties of successful central
nervous system drugs, NeuroRx 2 (2005) 541e553.
[40] I.V. Tetko, J. Gasteiger, R. Todeschini, A. Mauri, D. Livingstone, P. Ertl,
V.A. Palyulin, E.V. Radchenko, N.S. Zefirov, A.S. Makarenko, V.Y. Tanchuk,
V.V. Prokopenko, Virtual computational chemistry laboratory e design and
description, J. Comput. Aid. Mol. Des. 19 (2005) 453e463.
[41] D. Stephan, E. Salamon, H. Weber, U. Russ, H. Lemoine, U. Quast, KATP channel
openers of the benzopyran type reach their binding site via the cytosol, Br. J.
Pharmacol. 149 (2006) 199e205.
[42] D. Lamoral-Theys, A. Andolfi, G. Van Goietsenoven, A. Cimmino, B. Le Calvé,
N. Wauthoz, V. Mégalizzi, T. Gras, C. Bruyère, J. Dubois, V. Mathieu,
A. Kornienko, R. Kiss, A. Evidente, Lycorine, the main phenanthridine amar-
yllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that
display resistance to proapoptotic stimuli: an investigation of structure-
activity relationship and mechanistic insight, J. Med. Chem. 52 (2009)
6244e6256.